The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However, majority of MM patients relapse, and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including cellular therapies, monoclonal antibodies, and small molecules, are currently under investigation. In this review, we report novel drugs recently approved or under advanced investigation that will likely be incorporated in the future as new standard for MM treatment, focusing on their mechanisms of action, cellular targets, and stage of development.
From the *Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School;
†Section of Hematology and Oncology, Boston Medical Center; and
‡VA Boston Healthcare System, Boston, MA.
The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Reprints: Nikhil C. Munshi, MD, Dana-Farber Cancer Institute, 44 Binney St, D1B06, Boston, MA, 02115. E-mail: Nikhil_Munshi@dfci.harvard.edu.